Mr. Morin is an “outstanding litigator” and “a very thoughtful and creative lawyer who is very good at developing a case.”

Chambers USA 2020

Michael A. Morin

Washington, D.C. | Chicago
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
 
 

Michael Morin, a nationally recognized first-chair litigator, represents clients across industries in high-stakes IP trials and appeals. He serves as Global Vice Chair of the Intellectual Property Litigation Practice and Co-Chair of the Healthcare and Life Sciences Industry Group.

Mr. Morin represents leading companies — from startups to global leaders — in their most critical intellectual property matters, including multi-billion dollar cases involving many of the world’s best-selling drugs, medical devices, and software products. He regularly handles highly technical matters for clients in a range of industries including:

  • Pharmaceuticals
  • Biologics
  • Medical devices
  • Technology (Software/Hardware)
  • Consumer products

From the start of any engagement, Mr. Morin focuses on understanding a client’s business and goals — both for a specific litigation and as part of a long-term strategy. He develops early game plans and then leads teams to execute on those plans in trial, arbitration, or on appeal. He has developed an impressive track record of wins, and a roster of clients that he has successfully served for decades.

Complementing his trial work, Mr. Morin advises clients on their IP portfolios and strategies, assists with licensing and transactional issues, and counsels clients on their legal positions, responsibilities, and risk management.

Mr. Morin is widely recognized as a preeminent trial lawyer.

  • Praised as a “natural-born leader” and a “talented, extremely clever, hardworking and experienced lawyer” who “you can trust with your crown jewel assets.” He has the ability to “stand up in court and present complex subject matter in an even-handed, compelling way.” One client notes “the litigation profession is becoming increasingly uncivil, so it’s great when you get to deal with someone like Mike.” – IAM Patent 1000 2016-2019 (Gold ranking each year)
  • A “down-to-earth and likeable guy in court who is brilliant at simplifying complex technical material” and “maintains excellent command of his team and has real presence in the courtroom.” – IAM Patent 1000 2019-20 (Gold ranking each year)
  • “Fantastic oral advocate in court or arbitrations. Masterful at telling story and integrating complex facts and legal principles. Excellent overall team leader with focus on big picture and the client’s goals. Excellent writer too. Very ethical.” The Legal 500 US 2020
  • Recommended Lawyer for Life Sciences – The Legal 500 US 2017-18
  • Litigator of the Week, February 8, 2019, for MorphoSys v. Janssen win involving J&J’s blockbuster Darzalex® product – American Lawyer
  • Named a Life Sciences Star – Legal Media Group and Euromoney 2016-20
  • Named an IP Star and shortlisted for Outstanding Litigator: District of Columbia – Managing Intellectual Property 2019, 2020
  • Shortlisted for General Patent Litigator of the Year: D.C. – LMG Life Sciences 2018, 2019
  • Recommended for Patents – Who’s Who Legal 2016-20

Mr. Morin also devotes considerable time to pro bono activities, representing disabled veterans in civil matters and indigent defendants in criminal cases.

Mr. Morin is a faculty member of the Trial Advocacy College at the University of Virginia, and leads the Working Group on parallel district court and PTO proceedings for the Sedona Conference.

Mr. Morin’s representative experience includes serving as lead counsel for:

  • AbbVie in numerous litigations involving Humira®, the world’s best-selling drug, resulting in multiple trial, arbitration, and appellate wins
  • AbbVie in more than a dozen litigations involving numerous other innovative drugs, including Viekira®, Zemplar®, and Imbruvica®
  • Abbott in more than a dozen litigations involving numerous innovative medical device products (stents, catheters, mitral clips, heart valves, laser surgery devices, ICDs, pacemakers, and other products), resulting in multiple trial, arbitration, and appellate wins, as well as a US$400 million settlement involving coronary stents
  • Janssen (a Johnson & Johnson company) in litigation involving its innovative Darzalex® product, resulting in a complete win on summary judgment, and Litigator of the Week honors in the American Lawyer
  • Intellia Therapeutics in multiple matters relating to CRISPR/Cas9 gene-editing technology
  • Adobe in litigation involving its market-leading Acrobat® product
  • SAP in multiple patent infringement cases involving its market-leading business software
  • Neurocrine in litigation involving its innovative Elagolix® product
  • Quest Integrity in litigation involving furnace inspection technology
  • Astellas in litigation involving stem cells
Thought Leadership
  • Chapter Editor, “The Sedona Conference Commentary on Patent Litigation Best Practices: Parallel USPTO Proceedings,” (2014 – 2017) (multiple editions)
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.